MedTrace Logo

Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer

NCT02324543 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2023-07-21

Study results available
· View outcomes & findings →

Summary

This study will be looking at whether gemcitabine, taxotere, and xeloda (GTX) in combination with cisplatin and irinotecan is effective (anti-tumor activity) and safe in patients with metastatic pancreatic cancer.

Conditions

  • Metastatic Pancreatic Adenocarcinoma

Interventions

DRUG

Gemcitabine

IV on days 4 and 11 of a 21 day cycle

DRUG

Taxotere

IV on days 4 and 11 of a 21 day cycle

DRUG

Xeloda

Twice a day orally on days 1 through 14 of a 21 day cycle

DRUG

Cisplatin

IV on days 4 and 11 of a 21 day cycle

DRUG

Irinotecan

IV on days 4 and 11 of a 21 day cycle

Sponsors & Collaborators

  • Swim Across America

    collaborator OTHER

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    lead OTHER

Principal Investigators

  • Dung Le, MD · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
76 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2019-06-30
Completion
2020-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02324543 on ClinicalTrials.gov